MAPT and Alzheimer disease: For example a recent study tested the potential of 11C -Martinostat PET that binds to the epigenetic molecules of class I histone deacetylaces, showing that they are reduced in patients with AD and mediate the effects of Aβ and tau on brain atrophy and cognitive impairment in keeping with post-mortem studies [244].